I am Dr. Ramiro Gilardino, a physician and global health strategist working at the intersection of science, evidence, and policy.
Over more than two decades, I have worked across the biopharmaceutical industry, global organizations, and international professional societies, helping bridge scientific innovation with health technology assessment, market access, and healthcare decision-making.
My work focuses on connecting evidence, policy, and stakeholder perspectives to advance equitable access to innovation and strengthen the way healthcare systems evaluate and adopt new technologies.
What Drives My Work
Healthcare innovation succeeds when scientific evidence, policy, and patient perspectives evolve together.
I believe stronger evidence should lead to better decisions—and ultimately broader, more equitable access to innovation.
Areas of Expertise
Where science, evidence and policy meet
Helping organizations navigate complexity with purpose
-
Science, HTA & Evidence Policy
Developing evidence strategies aligned with HTA requirements, applying lifecycle approaches and real-world evidence to support informed decisions as evidence evolves.
Explore -
Health Policy, Partnerships & External Engagement
Engaging with policymakers, regulators and scientific societies to contribute to the policy environments in which healthcare innovation is evaluated and adopted.
Explore -
Corporate Strategy & Value Communication
Aligning organizational priorities with evidence and translating scientific value into clear narratives that inform strategic positioning, investment and business decisions.
Explore -
Patient-Centered Strategy & Innovation
Integrating patient perspectives into organizational strategy, evidence generation and healthcare innovation, so that development and access decisions reflect patient priorities.
Explore
Delivering Impact
Over 20 years of contributions at the interface of policy, access and innovation, from strengthening HTA and value frameworks across Europe and Latin America to shaping dialogue on health equity and system impact.
Highlighted Research- 20+ Years of international leadership
- 30+ Peer-reviewed publications
- Global Professional experience across Europe, the Americas and Asia-Pacific
- 10 International scientific and policy collaborations
-
Leadership in International Scientific Societies
Latest Insights
From the Blog
-
Real-World Evidence and Dynamic HTA: Are We Ready to Revisit Our Decisions?
Real-world evidence can help health technology assessment evolve beyond a single decision point. But are HTA systems prepared to revisit decisions as new evidence emerges? Reflections from GetReal 2026.
-
Lifecycle Approaches in Health Technology Assessment
Practical guidance for implementing Lifecycle Health Technology Assessment, including defining decision problems, sequencing assessment activities, and developing optimization criteria across different healthcare settings.
-
Understanding Health Technology Assessment Reforms Across International Agencies
How and why do HTA agencies reform their methods and processes? This study examines key reforms across 14 HTA agencies in Europe, Asia-Pacific, and North America, exploring the drivers of change, their interdependencies, and the implications for patient access to treatments.
Recent Peer-Reviewed Publications
Rigorous, transparent and inconclusive: what Europe’s first joint clinical assessment reveals about a framework trying to serve everyone
This perspective examines the European Union's first Joint Clinical Assessment (JCA), using tovorafenib for pediatric low-grade glioma to identify challenges in implementing the EU Health Technology Assessment Regulation. It highlights tensions between methodological rigor and evidence feasibility, limitations in comparator selection, gaps in patient and caregiver considerations, and the absence of mechanisms for updating assessments as evidence evolves. The paper proposes practical and structural improvements to strengthen the relevance of JCAs for healthcare decision-making.
Reframing patient-centered strategy: why life science organizations need a Chief Patient Officer (CPO) function
This white paper proposes the Chief Patient Officer (CPO) as a strategic organizational function to integrate patient perspectives across clinical development, evidence generation, market access, and health policy. It outlines five core capabilities—lifecycle stewardship, evidence integration, governance and standards, ecosystem activation, and translation into decisions, and illustrates their application through precision oncology and multiple sclerosis. The paper argues that embedding patient evidence into enterprise-level decisions can improve healthcare system readiness, reduce access barriers, and translate scientific innovation into measurable patient impact.